Date: 25-26 May 2021 Venue: InterContinental Dubai Festival City Businesses, key brands, entrepreneurs, and individuals from the converging sectors of AI, blockchain, IoT, and Quantum Tech, are invited to attend the AIBC UAE to be held on the 25th to 26th May 2021, at the InterContinental Dubai Festival City, in the emirate of Dubai. One of the globally acclaimed events for AI, blockchain, crypto, and other emerging technologies, this 2-day summit will witness a distinguished selection of delegates, policymakers, and industry veterans from all over the world. Owing to the international support and growing interest in evolving tech, AIBC Summit has become a popular event on the world forum for conferences and expos, showing continual growth every year. The warm and luxurious venue of the event, the Intercontinental Dubai Festival City, in Dubai, offers the perfect platform to bring together the thought leaders of Asia, Africa, America, and Europe, on a single unified platform. Further, with the support and sponsorship from the local government, connectivity to the major tech hubs in the industry, and vaccinations rolling out at a speedy pace, Dubai offers AIBE a conducive environment to host this large-scale event. The AIBC Expo is a hybrid event witnessing a classy business layout of the products and evolving tech solutions that are touted as the future of the finance industry. Attendees can avail the benefit of two complementary supershows, AIBC Dubai and AGS Dubai, in this single world-class event. Industry giants can get in-depth insights into this emerging industry with the Standard Tickets offering full access to:

• The Expo
• Conferences & workshops
• Networking drinks
• Informative startup pitches
• Entertaining VVIP Awards Dinner nights
• Closing dinner nights
• and much more.

There are more lucrative perks for the Premium and Platinum entry tickets. The Summit will witness some eminent industry leaders sharing their opinions and discussing some interesting topics centered around the agenda of the conference. At the other end of the spectrum, the virtual expo will unite exhibitors, panelists, and delegates for both brands across one floor to leverage the investment potential of the emirate business fraternity. The AIBC UAE Summit guarantees the optimum conference-unwind balance, an event that sets the bar in its niche. Given the COVID-19 pandemic, the organizers of the summit are well-equipped to take utmost care of the customers and are committed to increasing their standards of cleanliness. For more information about tickets to the event, please visit https://ibn.fm/yjtKs.

• Splash CEO and Chairman Robert Nistico took Red Bull North America from zero to $1.65 billion in annual sales
• Acquisition of Copa Di Vino in December was latest demonstration of Nistico and his quality leadership team recognizing accelerating trends
• Splash’s product portfolio is comprised of alcoholic and non-alcoholic brands including TapouT performance beverages, the official training partner of the WWE
• Splash’s sales doubled in the 1st Quarter 2021 to $2.4 million compared to 4th Quarter 2020. Almost reached the sales for the whole year 2020 of $2.9 million

George Clooney. Sean “Puffy” Combs. Ryan Reynolds. Robert Nistico. While the first three names likely ring a bell, Nistico is probably more of a mystery. Nistico may not be a celebrity entertainer, but he does have a common thread with Clooney, Combs and Reynolds insomuch that he’s been a part of successful beverage brands. Nistico has spent three decades in the beverage industry, including being the fifth employee and SVP/General Manager of Red Bull North America, where he led the start-up from zero sales to $1.65 billion annually. He also founded Marley Beverages, which was acquired in 2017 by New Age Beverages Corporation (NASDAQ: NBEV) (https://ibn.fm/uBYVK), and held executive positions at Diageo (NYSE: DEO), Republic National Distributing Company and the Gallo Wine Company. Nistico has now brought all those years of experience to upstart Splash Beverage Group (OTCQB: SBEV), where he has assembled a formidable portfolio of brands that are aligned with consumer trends. The Fort Lauderdale, Florida-based company has diversified beverages in the product bag, a strategy that de-risks operating in the highly competitive business while also allowing for cost-effective synergies across production and distribution channels. Splash’s flagship non-alcoholic drink line is TapouT, a brand originally made famous in mixed martial arts (“MMA”) circles before transitioning into a lifestyle brand via a joint venture in 2015 by World Wrestling Entertainment (NYSE: WWE) and BlackRock’s (NYSE: BLK) Authentic Brands Group. TapouT performance drinks, the official training partner of the WWE, competes with the likes of Gatorade and Powerade, touting a far more complete package of electrolytes and vitamins than its peers. Splash also offers a variety of alcoholic beverages, including Salt Naturally Flavored Tequila, Copa Di Vino “wine by the glass,” and Pulpoloco Sangria. All three are in the thick of consumer trends in their respective categories. Salt is a Mexico-made, 100% blanco agave 80 proof tequila, a spirit category experiencing strong year-over-year growth, momentum energized in part by Clooney’s Casamigos brand that sold in 2017 to Diageo for up to $1 billion (https://ibn.fm/wUBB5). After 6.6% growth in the category for 2018 to 2019 to 19.8 million cases, data suggests a similar increase in 2020 (https://ibn.fm/QmBOQ). Innovation is at the heart of the “wine by the glass” trend, where solutions such Copa Di Vino’s remove obstacles related to retaining freshness in premium wine that can be enjoyed anywhere without the need for a bottle, corkscrew or glass. After turning down offers twice on CNBC’s Shark Tank, Copa founder James Martin sold the brand to Splash in December, where it is now on shelves in over 13,000 retail locations (https://ibn.fm/gmxzI). Splash imports its Pulpoloco Sangria, the quintessential summer drink, from Spain. Again, getting in front of trends, particularly those that appeal to brand-loyal millennials, Pulpoloco is packaged in a low-carbon footprint, biodegradable paper can (called a catocan) that serves a double purpose of extending the shelf life of the product without using preservatives. These brands are part of Splash’s strategy to quickly develop and/or accelerate pre-existing brands to exit for cash events. Nistico’s acumen and network were instrumental in attracting top talent committed to the mission. The team includes President and CMO William Meissner, VP of Product Development Sanjeev Javia, CFO Dean Huge and Aida Aragon as SVP of national accounts. Much like Nistico, the names may seem a bit unassuming until it is understood that they have held leadership positions at companies such as Sweet Leaf and Tradewinds Tea, SoBe Beverages, Fuze, Muscle Milk and more, not to mention Javia advising on nutritional plans for star athletes, including Tom Brady, Kurt Warner and Curt Schilling. Similarly, Huge was the 14th person hired at Catalyst Energy Corp., which was named Inc. Magazine’s ‘Fastest Growing Company’ as it grew to 440 people during his tenure. The results speak volumes to the success Splash is achieving. After starting 2020 with sales of $112,003, revenue for the year climbed to $2.98 million, including $1.24 million in the fourth quarter. That sales momentum didn’t include the Copa Di Vino acquisition, which was completed in December—an achievement which should have investors on the lookout for what can be accomplished when those sales show up on the books in 2021. Additionally, Splash’s sales doubled in Q12021 to $2.4 million compared to Q42020, almost reaching the sales for the whole year 2020 of $2.9 million (https://ibn.fm/Gxc4L). For more information, visit the company’s website at www.SplashBeverageGroup.com. NOTE TO INVESTORS: The latest news and updates relating to SBEV are available in the company’s newsroom at https://ibn.fm/SBEV

• Retail investors are more important now than ever, making Sequire a powerful tool
• Data on who investors are, what they invest in is valuable asset
• SRAX plans on creating even more value to platform through development of Sequire Investor Community

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies, has announced that Sequire, its proprietary SaaS platform, has reached a significant milestone — 5 million retail investors (https://ibn.fm/CsE8n). “Retail investors are more important now than ever, as they have been driving the market, and companies are starting to pay attention,” said SRAX founder and CEO Christopher Miglino. “Data on who investors are and what they invest in is a valuable asset to every public company. This data provides us deep insights into trends and movements of all types of investors.” SRAX’s Sequire platform is an operating system that publicly traded companies use to, first, track their shareholders’ behaviors and trends and then, based on the insights they gather from that data, engage current and potential investors across marketing channels. Sequire was officially announced in May 2020 as a rebrand of SRAX’s investor intelligence platform (https://ibn.fm/bJE68). The name — Sequire — captures the platform’s main objective to both acquire and secure investors for publicly traded companies. “We are thrilled to announce the new brand, giving the platform its own identity separate from SRAX,” said Miglino. “It’s also arriving at an opportune time as we are developing new intelligent technologies to further provide public companies the tools to reach and engage their shareholders.” The appeal of the platform seems evident as the community has grown to reach a network of more than 5 million influential, forward-thinking investors in barely a year; the Company plans on creating even more value through the development of the Sequire Investor Community. The Sequire Investor Community is a place where investors can convene, learn and share on a wide range of industry-related topics, the Company noted. More opportunities, education and news within this network will accompany the multiple investor events already slated for this year. One of those events is the 2021 LD Micro Invitational, available via the Sequire virtual events platform and slated for June 8–10, 2021 (https://ibn.fm/gYldT). The premier, three-day virtual investor conference has gained a reputation for being one of the most influential conferences in the small-cap space. An event designed specifically for newcomers and companies on the “cusp” of doing big things, the invitational is expected to include an estimated 180 companies; each company will offer a 25-minute presentation. In addition, this year’s agenda features several leading keynote speakers and a one-time attraction: the LD Micro Hall of Fame, which will include the top 50 companies out of the nearly 2,000 that have attended LD Micro events through the years. SRAX, based in Los Angeles, is a digital marketing and data management technology company providing marketers, content owners and consumers tools to unlock the value of data. The Company’s technology unlocks data to reveal brands and content owners’ core consumers and their characteristics across marketing channels. SRAX is committed to building increasingly reliable data sets across many industry verticals, accurately identifying target consumers for brands and companies in the CPG, investor relations, luxury, and lifestyle spaces, keeping those brands ahead in the competitive curve with high-quality data. For more information, visit the company’s websites at www.SRAX.com and www.MySequire.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Social selling is when salespeople use social media to find and engage with new prospects.
• SHRG is dedicated to being a leader in the direct-sales arena.
• Sharing Services is committed to staying ahead of marketplace trends, fulfilling needs, consistently increasing shareholder value.

Social selling is the latest business model in the direct-sales world, and the strategy has been proven to increase company revenue by 16% (https://ibn.fm/hrP6O). Sharing Services Global (OTCQB: SHRG) and its primary subsidiary Elevacity Holdings LLC. are leveraging a modern take on the traditional approach to reach out to a growing number of consumers as well as potential business partners. Calling social selling “sales 2.0,” a recent article noted that “social selling is when salespeople use social media to find and engage with new prospects. Salespeople use social media to provide value to prospects by answering open-ended questions, responding to comments and sharing content throughout the buying process — from awareness to consideration, until a prospect is ready to buy.” The same article reported that “sales reps who use social selling find on average 45% more opportunities. In addition, social selling helps best-in-class companies achieve a 16% gain in year-over-year revenue. That’s four times better than companies that don’t use social selling.” SHRG has always been dedicated to being a leader in the direct-sales arena, working to be nimble and adaptable in order to offer its sales force the most compelling, effective support available. In fact, one of the company’s principles is speed. “Speed is important,” the corporate website states. “The speed of change requires timely decisions. Otherwise we will watch others who complete their research and make their decisions faster.” Sharing Services is committed to always staying ahead of marketplace trends, fulfilling needs, creating sustainable enterprise growth and consistently increasing shareholder value. This commitment is reflected in the Happy Co., the new brand identity of SHRG’s wholly owned subsidiaries Elevacity Holdings LLC and Elevacity U.S. LLC. (https://ibn.fm/05p2J). One of the fastest-growing companies in the social-marketing and direct-selling arenas, the Happy Co. has become the category creator for Happy Coffee and a recognized leader in natural nootropics. The Happy Co. has created a business model to make happiness happen for everyone involved with the company (https://ibn.fm/GN0Cq), and this model includes functional beverages, capsules, patches and creams. Each product is deliberately designed and formulated to elevate mood, boost energy, reduce stress, enhance sleep, increase muscles, minimize fat, tighten skin and help consumers look, feel and perform like a younger person. Sharing Services Global Corporation is a publicly traded diversified company dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies. The Sharing Services combined platform leverages the capabilities and expertise of various companies that market and sell products direct to the consumer. Its primary division includes Elevacity U.S., LLC, a sales and marketing company based on utilization of independent contractors as the sales force. For more information, visit www.SHRGInc.com and www.TheHappyCo.com. NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• British Columbia-based investment holding company Clean Power Capital Corp. recently held its annual general and special meetings of shareholders
• Shareholders voted to sustain the company’s new investment directive, which includes focusing on renewable power initiatives and bio-medical plus naturopathic sectors
• Clean Power’s CEO announced his resignation following the meeting and he will be succeeded by majority-owned investee PowerTap Hydrogen Fueling Corp.’s CEO
• The company has also launched two new marketing initiatives to increase its investment profile with the general public
• PowerTap appointed a former Shell Oil Products US executive to its advisory board

Holding company Clean Power Capital (NEO: MOVE) (FWB: 2K6A) (OTC: MOTNF) charted a new course amid last year’s pandemic-depressed months, turning its stated mission to the renewable energy sector as an area of investment focus and placing special emphasis on its majority equity-owned investee PowerTap Hydrogen Fueling Corp. On Monday, March 15, the company held its Annual General and Special Meeting at which shareholders approved the company’s amended and restated investment policy.

Following the meeting, Clean Power CEO Joel Dumaresq stepped down from his position with the company but will continue to function as Clean Power’s chief financial officer on an interim basis. Raghunath (Raghu) Kilambi, the CEO and CFO of PowerTap Hydrogen, was named the new CEO and president of Clean Power in Dumaresq’s place (https://ibn.fm/IscOe). Kilambi continues to function as PowerTap’s CEO as well.

PowerTap has seen the strength of its platform rise under Kilambi’s leadership in recent months, particularly through agreements that have brought the powerhouse Andretti Group into partnership with the company for fuel station sites, marketing and board leadership (https://ibn.fm/65EHI).

Kilambi has over 25 years of global business experience in public and private investments, building businesses and creating shareholder value. He has raised more than $1 billion of equity and debt capital for private and public companies in the United States and Canada, and has been involved in many M&A acquisitions and exits. His experience with investments in emerging technologies will be an asset for Clean Power as it continues to seek additional investment opportunities under its new mission statement.

That investment policy specifically states the company will focus on renewable energy, which may include, without limitation, hydrogen & fuel cell technologies, wind power, solar power and geothermal power; and bio-medical, pharmaceutical, and naturopathic sectors, which may include medical or recreational cannabis.

Clean Power has also announced a pair of decisions to advance its investment profile among the public. The company entered into an investor relations advisory services agreement on March 10 with 1830012 Ontario Limited, operating as Circadian Group to create a customized positive investment image and communicate that image to the investment community. In addition, the company retained Mountain Capital Corp. on March 8 to provide strategic digital media services, as well as marketing and data analytics services, for a three-month period, according to the annual meeting news release.

PowerTap also announced development of its advisory board through the appointment of David Bray, former corporate officer/general manager of Shell Oil Products US. Bray’s company, Bray Retail Consulting, LLC will also join PowerTap in a consulting role under an exclusive one-year assignment.

The consultancy will focus on critical product development and services to accelerate the deployment of PowerTap’s proprietary modular 1,250 kg hydrogen production and dispensing technology as part of a planned hydrogen fueling station network launching in California with the Andretti Group’s assistance. The company will then use Andretti’s connections to build the network into other parts of the country.

Bray is a seasoned Shell executive whose more than 30 years in the industry included serving as the general manager of several groups at Shell, including Strategy/Business Development, Fuels and Marketing, and Americas Aviation.

“Regarding hydrogen, we are at the starting line in terms of the growth opportunity for its use as a transportation fuel. I believe that hydrogen will play a critical role in meeting the energy needs of the Americas going forward,” he stated.

For more information, visit the company’s website at www.CleanPower.Capital.

NOTE TO INVESTORS: The latest news and updates relating to MOTNF are available in the company’s newsroom at https://ibn.fm/MOTNF

• The increased driving range and expansion of charging outlets are expected to trigger widespread adoption of EVs, including commercial EVs
• The commercial EV segment is projected to grow at a 41.1% CAGR from 2020-2028 and is likely to influence the purchase of other types of EVs, further benefiting Ideanomics’ Mobility division
• Ideanomics Capital division, through wholly owned subsidiary Timios, is set to benefit from the pandemic-driven growth currently being witnessed in the housing market

The global electric commercial vehicle market is expected to grow at a CAGR of 41.1% from 2020 to 2028, reaching a little over 2 million units in sales on the back of advancements in battery technology, electrification of public transportation fleets and stricter government regulations on pollution, per a Research and Markets forecast (https://ibn.fm/AZ0TM).

Similarly, a 2020 Deloitte article (https://ibn.fm/UAh8f) noted that the removal of two of the biggest barriers for consumers, namely driving range and the lack of charging infrastructure over the next few years, portends good tidings for the electric vehicle (“EV”) industry. The article further observed that the proliferation of commercial EVs (lorries, trucks and vans) and mass transit vehicles (buses) would instill even more confidence in consumers as to the reliability of EVs, influencing them to purchase the other types of EVs.

Based on these predictions, Ideanomics (NASDAQ: IDEX) is positioned favorably, given its Ideanomics Mobility division is focused on the EV market. This division comprises over five companies, including Medici Motor Works, which operates in the electric commercial vehicle segment, offering zero-emission trucks, vans and buses. Others are Mobile Energy Global (“MEG”), Wireless Advanced Vehicle Electrification (“WAVE”), Treeletrik, Energica, Solectrac and Silk EV.

“2020 was the year for passenger EV… But 2021 is the year that the commercial (‘EVs’) start to become mainstream; this is when companies like Ideanomics and others are going to shine,” stated Ideanomics CEO Alf Poor in a presentation at the 23rd Annual Needham Growth Conference (https://ibn.fm/H74nP) earlier this year. Alf went on to quote Bloomberg New Energy Finance (“BNEF”), which estimates that global commercial EV sales will reach 1.2 million units in 2023.

Ideanomics, which wholly owns Medici Motor Works, is set to capitalize on this expected growth in demand, which is projected to remain consistent through 2040, per BNEF’s long-term electric vehicle outlook. By 2040, EVs will account for 67% of all public buses and 24% of all light commercial vehicles. At the same time, Ideanomics’ Treeletrik and Energica subsidiaries, manufacturers of two-wheelers, will also benefit as 47% of all motorbikes sold in 2040 will be electric (https://ibn.fm/VXfmf).

The future also holds great promise for IDEX’s second division, Ideanomics Capital, which focuses on providing disruptive fintech solutions covering a broad range of financial services. The division is made up of five companies: Timios, DBOT, Liquefy, Intelligenta and Technology Metals Market (“TM2”). In his presentation, Alf singled out Timios, praising its data-driven approach to closing more property refinancing and purchasing within the broader real estate sector.

But, why Timios? What has made real estate stand out? The housing market is currently “in a frenzy like no other since the 2008 crisis”, occasioned by higher demand for housing than there is supply (https://ibn.fm/eXDbm). The pandemic is credited for this phenomenon because some companies relocated at the height of the outbreak, causing surges in demand for housing in certain cities. Further, the work-from-home policy encouraged employees to upgrade their homes, either through renovations or by purchasing new homes, with the latter contributing to the surge in demand (https://ibn.fm/Q6can).

Remarkably, in his presentation, Alf had foreseen this imminent vibrancy of the housing market, which, as he had observed, would greatly favor Timios. “Companies like Timios can make a lot of money. These guys made $3 million EBITDA in December alone. So, we’re going to expect big things from them,” Alf added. Over the coming period, Ideanomics plans to inject more capital into Timios to help it grow more efficiently.

For more information, visit the company’s website at www.Ideanomics.com.

NOTE TO INVESTORS: The latest news and updates relating to IDEX are available in the company’s newsroom at https://ibn.fm/IDEX

• Approximately 50% of patients who have bladder cancer will see a recurrence of the condition – often due to poor margin visibility
• White light has been the standard procedure during cystoscopies, but is only beneficial if tumors protrude from the bladder wall
• Blue light cystoscopies address this issue, increasing the odds of removing more cancerous cells and reducing the recurrence of the cancer
• The i/Blue Imaging System(TM) improves surgical technique by combining both white and blue light capabilities on one screen without the necessity of switching between two images
• Imagin Medical Inc. is currently moving toward commercializing the system, expecting to complete the product in 2022

Approximately 50% of patients who suffer from non-muscle-invasive bladder cancer will relapse. Even with the rates of local recurrence after definitive therapy improving, research indicates that management of the disease remains a challenge. Urothelial carcinoma, the most common type of bladder cancer, continues to exhibit high rates of recurrence (https://ibn.fm/4HXcP).

The primary treatment for recurrence focuses on cytology, stage, and clinical characteristics. A particular area of interest is identification and causes/predictors of urothelial carcinoma recurrence. Differentiating management of recurrent carcinoma from treatment of primary carcinoma has generated limited progress, but the research indicates that organ-conserving and endoscopic therapies may be effective, especially by identifying patients who are facing a higher risk of early recurrence.

This is where technologies such as Imagin Medical’s (CSE: IME) (OTCQB: IMEXF) i/Blue Imaging System(TM) may prove effective by enhancing tumor visualization and resection, and potentially lowering recurrence rates as a result.

Focused on establishing a new standard of care in the visualization of cancer during minimally invasive procedures, Imagin Medical’s primary focus is bladder cancer, the sixth most prevalent cancer in the U.S. and the third most common on men. Due to its high recurrence rate, patients who have had bladder cancer require years of follow-up testing and procedures to catch recurrence early, making it one of the most expensive cancers to treat (https://ibn.fm/tus7H).

The conventional method used to visualize bladder cancer during surgical procedures is called a cystoscopy. Cystoscopies allow medical providers to see inside the bladder using a thin, lighted, flexible tube called a cystoscope, which uses white light to illuminate the area. White light has been the standard of care for decades and is used by more than 90% of the cystoscopy procedures. While white light effectively shows the landscape of the bladder, it is not effective in visualizing all cancerous tissue that may be present in the bladder, only tumors that protrude above the surface.

Since 2010, the use of blue light paired with a reactive contrast agent during cystoscopies has been expanding as a promising new visualization method that highlights cancerous cells, including margins and flat tumors along the bladder wall. The problem with using blue light during cystoscopies is that the images are not in real time, requiring surgeons to switch back and forth, during the intervention, between the real-time white light image and the blue light image that highlights the cancer.

Imagin’s i/Blue Imaging System aims to address these shortcomings. Combining the effectiveness of blue light cystoscopy with proprietary technology, the i/Blue Imaging System will improve surgical technique by displaying both white and blue light images simultaneously side-by-side in real time on one monitor. This innovation will enable the surgeon to view cancerous cells and their margins in context for more complete removal eliminate the need to switch back and forth to resect the cancer.

Imagin is currently moving toward commercialization of its technology, with the Food and Drug Administration approval process underway. The company is working with Maine-based Lighthouse Imaging, an FDA registered and ISO 13485:2016 certified manufacturer, to finalize the system design for manufacture. The product is on track for completion in 2022 (https://ibn.fm/TKiU1).

Once the goal of changing bladder cancer visualization has been realized, Imagin will build on the i/Blue Imaging System’s technology to facilitate other minimally invasive procedures, including laparoscopic, colorectal, and thoracic that use a variety of contrast dye agents and illumination sources. Imagin is working to improve upon past technology, create better patient outcomes, and incur fewer costs in the process.

For more information, visit the company’s website at www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

• Mobius.Bet will be showcased in all 8 stadiums during the Brazil FIFA World Cup Soccer qualifiers – the opening salvo of its launch into the lucrative Brazilian market
• There will be an estimated 35 to 40 million viewers per match
• With over 76 million gamers, Brazil is the largest and fastest-growing Esports and gaming market in Latin America

Mobius Interactive, an online Esports and gaming operator, is expanding into the Brazilian market. The Company announced in a recent press release (https://ibn.fm/Pj2uL) that the Mobius.Bet brand will be displayed prominently in every stadium and on Globo TV for all eight World Cup qualifiers in Latin America. Soccer is the biggest sport in the world and Brazil is a soccer powerhouse. Brazil holds more World Cup victories than any other team; they have qualified for every World Cup they have entered. The 2021 qualifiers begin June 3 and run through November 16. These critical matches will attract an average audience of 35 million people on Globo TV. The match against Argentina, Brazil’s biggest rival, is expected to top 40 million viewers. In the words of Mobius Interactive CEO Lynn Pearce: “As we go to market in Brazil with this great opportunity, Mobius.Bet will be showcased on Globo TV and in every stadium, featuring the best teams in Latin America. I don’t believe we could have wished for a better launch pad to introduce ourselves to the sports enthusiasts and betting community in this region. The team at Mobius are ecstatic to be a part of these events; we are just as excited about the games as the fans are – all the way to Qatar in 2022.” These stadiums have enormous capacities (between 38,755 and 78,838). While these crowd potentials are very impressive, remember you are buying into the massive Brazilian TV audience. Globo TV Network reaches 99.5% of potential viewers, practically the entire Brazilian population of over 211 million. With over 76 million gamers, Brazil is the biggest Esports and iGaming market in Latin America. This industry is currently experiencing unprecedented growth. Mobius is strategically positioned, poised to take full advantage of this lucrative, emerging market. The Mobius team launched in September 2020, after years of working and consulting within the iGaming industry. With over 40 years of hands-on industry experience and having launched over 30 successful products globally, Team Mobius knew exactly what modern players wanted. Mobius is now uniquely positioned to offer today’s sophisticated players the best customer service possible. Our loyalty and gamification programming is meticulously designed by top industry experts, to engage and retain Esports enthusiasts and sports betting players alike. Mobius launched three diverse brands within an incredible timeframe of only three months in 2020, setting a record in the gaming industry: Mobius.Bet, AragonCasino.com, and ClubDouble.com. Mobius.Bet is designed to appeal to Esports consumers aged 18 to 38, combining loyalty programs, targeted gamification, and product merchandising into one seamless package. Catering to consumers aged 21 to 45, AragonCasino.com brands itself along the lines of medieval and modern fantasy, mimicking elements of The Walking Dead and Game of Thrones. Club Double targets the 30 to 65 age demographic, showcasing a theme that combines classic old Hollywood and vintage Miami/Las Vegas. Mobius has set itself apart from other gaming platforms through affiliate marketing groups, a focus on Esports, real-time customer relationship management, and a unique loyalty and gamification program. Now it’s time to bring the premier Mobius gaming experience to Brazil. For more information, visit the company’s website at www.MobiusInteractive.Ltd. NOTE TO INVESTORS: The latest news and updates relating to Mobius are available in the company’s newsroom at http://ibn.fm/Mobius

• RYAH has released April 2021 Patients Patterns in New York Report to bring invaluable data-driven insights within the plant-based health industry amid recent recreational cannabis legislation change in this state.
• The company leveraged data from 4,387 New York patients within the RYAH Data ecosystem to discover New York-based patients’ profiles, including their preferences and medical reasons for use.
• As an authority in dose-control technology for plant-based medicine, RYAH appears well placed to capitalize on growing market opportunities.

RYAH Group (CSE: RYAH) (formerly known as Prime Blockchain Inc.) has announced the release of its “April 2021 Patients Patterns in New York Report,” covering data generated by 4,387 patients from New York who logged their sessions within the RYAH Data ecosystem between January 1, 2018, and April 15, 2021 (https://ibn.fm/ScF8T). As an authority within the dose-control technology for plant-based medicine, RYAH leverages access to a wealth of data helping open up new knowledge-enabled possibilities within the health industry. The newly published report is the latest such initiative — especially invaluable since the recent legislative approval of recreational cannabis in March 2021.

Home to one of the wealthiest cities in the world, New York state accounts for 8% of US GDP. It is expected to become one of the largest US plant markets, with recreational cannabis sales potentially reaching $1.2 billion by 2023 and up to $4.2 billion by 2027. With these market expectations, it is of critical importance to understand who a New York-based patient is, what their preferences are, and what medical conditions they use cannabis for.

As a data analytics health care company collecting anonymized data generated by patients, RYAH is ideally placed to answer these questions. The Company is committed to developing cutting-edge technology to generate powerful analytics by combining dosing data with lab test information and patient feedback to create a personalized self-optimizing experience.

The report gives invaluable insights into the New York medical cannabis space, comparing it to the national average. It reveals that these patients are more likely to be male (65.5%) than patients at the national level (54.8%) while they have slightly less experience with the plant and use it less frequently. For example, 7% of patients from New York use it daily, compared to the national average of 8.4%. On the other hand, and in line with national averages, New York patients prefer cultivars with higher THC content or a CBD-rich profile. More sessions from New York-based patients were logged on the RYAH platform for anxiety, social anxiety disorder, and ADHD than patients from other parts of the country. RYAH Data ecosystem also reveals that conditions such as stress and depression are more prevalent in New York patients.

After launching in a limited capacity in 2016, New York State’s medical cannabis program served more than 143,000 patients. In March 2021, the state approved the legislation covering recreational cannabis, becoming the 15th state to legalize recreational use (https://ibn.fm/rFWL5). Several amendments are introduced to improve access to medical cannabis, covering a wide range of qualifying conditions, including cancer, HIV, Parkinson’s disease, multiple sclerosis, spinal cord injury, epilepsy, inflammatory bowel disease, neuropathy, Huntington’s disease, PSTD and chronic pain. As a go-to provider of data analytics expertise for the plant-based medical industry, RYAH appears ideally placed to capitalize on the growing market opportunity as New York positions itself to become one of the nation’s largest markets of legal cannabis and the plant-based legislation continues to evolve nationwide.

For more information, visit the company’s website at www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the Company’s newsroom at https://ibn.fm/RYAH

• April analyst reports all point to a bright future for Cybin
• “CYBN is a true multi-molecule company that’s not being reflected in its valuation,” reports Stifel
• “With a relatively small 5% penetration, Cybin could achieve ~$8B in sales in the U.S. and EU5 combined,” notes Roth

A series of recent analyst reports bodes well for Cybin (NEO: CYBN) (OTCQB: CLXPF), a leading biotech company focused on progressing psychedelic therapeutics. April reports from Canaccord Genuity equity research company, Stifel GMP (https://ibn.fm/aQ9af) and Roth Capital Partners (https://ibn.fm/YkBNb) all categorize Cybin as a buy, with Stifel increasing its price target from $5 to $11, Roth noting a $10 per share price target, and Canaccord coming in at $8.

In its report increasing Cybin’s price target, Stifel noted that “CYBN is a true multi-molecule company that’s not being reflected in its valuation.” The report further observed, “CYBN has been progressing rapidly along its path of developing a pipeline of novel psychedelic molecules, transforming the company from a single molecule strategy to a more diversified one with stronger IP opportunities.”

The report noted that the company’s proprietary CYB003, a novel 2nd-generation tryptamine, has undergone proof-of-concept studies and that the company is targeting alcohol use disorder, a relapsing disease with high unmet needs, a large addressable market and low competition. “We believe CYBN’s shares have a direct pathway for over ~3.5x upside near term as neither its primary candidate nor its first novel candidate — expected to enter clinical trials in 2021 — is fully accounted for in its valuation, offering investors with an attractive entry point,” the analysis concluded.

As a basis for initiating coverage of Cybin, the Roth analysis reported the following: “Overlooked by the pharmaceutical industry, Cybin found, in our opinion, ingenious ways to improve potency and delivery of psychedelic drugs by reformulation and by exploring deuterated analogues. Along the way the company created novel intellectual property to fend off competition.

“According to a recent study by Imperial College London, psilocybin may actually be superior to an SSRI [selective serotonin reuptake inhibitor], escitalopram, in patients suffering from major depressive disorder,” the report continued. “However, each psilocybin treatment session may last 6-8 hours, when administered orally. Cybin’s sublingual formulation bypasses the stomach, as the drug enters the bloodstream through the oral mucosa for faster onset of action. . . . TRD (treatment resistant depression) impacts over 1% of the population, unfortunately. With a relatively small 5% penetration, Cybin could achieve ~$8B in sales in the U.S. and EU5 combined, according to our calculation.”

In its report, Canaccord noted that an academic group from Imperial College London published long-awaited results from its Psilodep-RCT study in the “New England Journal of Medicine.” The study analyzed the treatment of patients with long-standing, moderate-to-severe major depressive disorder (“MDD”) over a six-week period.

“The results did not hit on the primary endpoint but were in favor of psilocybin on the primary and every secondary outcome measure,” the analysis noted. “We view the results from this relatively small trial as encouraging for the potential use of psilocybin in the depression setting. We also believe the results support the investigation of psilocybin in larger, multi-center trials, which CYBN eventually expects to pursue.”

An earlier Canaccord Genuity report noted that Cybin is using a proprietary drug discovery platform combined with novel delivery and formulation technologies to develop innovative psychedelic therapeutics to treat psychiatric disorders. After hosting several investor meetings with Cybin executives, Canaccord reported that “investor focus was on the upcoming Phase 2 program for [Cybin’s] lead product, CYB001, which is a sublingual film formulation of psilocybin to treat major depressive disorder (“MDD”). CYBN expects to start a Phase 2a trial in Jamaica (West Indies). The company then expects to file an investigational drug (“IND”) application and start a Phase 2b trial, which will include US sites, soon after.” Observing that “all eyes are on the Phase 2a data,” Canaccord called CYB001 a near-term catalyst for CYBN.

Canaccord also reported that investors are focused on the evolving intellectual property (“IP”) situation around psilocybin and that CYBN intends to uplist to a major US exchange shortly. “So we note this is a very interesting period for CYBN both as a company and as a stock, and we are reiterating our BUY rating,” the report concluded.

Cybin Corp., a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug- discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN